From: A novel TCGA-validated programmed cell-death-related signature of ovarian cancer
Gene | Physiological functions | Inflammation/immune responses | Roles in OC/other cancers |
---|---|---|---|
PPP1R15A | enhances antitumor immunity [37] | influences peritoneal metastasis of OC [38]. | |
OGG1 | promotes DCs activation [41], related to NFκB-dependent inflammatory [42]. | arrests cancer cell proliferation [43]. cooperates with TP53 mutations in OC [44]. increase OC susceptibility [45]. induces PARP resistance [46]. | |
HERC1 | neurodevelopment, maintain genomic integrity, and cell growth [47]. | immune response [47]. | regulates breast cancer metastasis [48]. |
CASP2 | participates in apoptosis process and genomic stability [49]. | backs up efficient expression of type I interferon [50]. | affects colony formation of cancer cells and chemotherapy resistance [51]. |
CAAP1 | inhibit apoptosis pathway [52]. | interacts with B or T cells [52]. | regulates the apoptosis and autophagy in gastric cancer [53]. |
RB1 | regulates cell cycle progression [54]. | ||
ZBP1 | mediates innate immunity, balance inflammation and cell death [58]. | potential target for immune checkpoint blockade inhibitors [59]. | regulates cell death in OC via the RIP3/MLKL pathway [60]. |
CD3E | located on surface of T lymphocytes [61]. | adaptive immune response [61] and conduct T cell receptor transmission [62]. | a prognostic biomarker for OC patients [63]. |
CLTCL1 | control intracellular traffic, tumorigenesis and cell proliferation [64, 65]. | (-) | a favor factor for breast cancer [66]. |
CEBPB | cell proliferation, differentiation, cell death, and tumorigenesis [67]. | monocyte-to-macrophage differentiation [68]. | mediate the PARP resistance in OC [69]. |